dc.contributor
Institut Català de la Salut
dc.contributor
[Brose MS] Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, USA. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Elisei R] Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. [Bastholt L] Department of Clinical Oncology, Odense University Hospital, Odense, Denmark. [Führer-Sakel D] Department of Endocrinology, Diabetes and Metabolism and Clinical Chemistry, University Hospital Essen, Essen, Germany. [Leboulleux S] Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France. Department of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Geneve, Switzerland
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Brose, Marcia
dc.contributor.author
Bastholt, Lars
dc.contributor.author
Führer-Sakel, Dagmar
dc.contributor.author
Leboulleux, Sophie
dc.contributor.author
Capdevila Castillon, Jaume
dc.contributor.author
ELISEI, ROSSELLA
dc.date.accessioned
2025-10-25T05:39:41Z
dc.date.available
2025-10-25T05:39:41Z
dc.date.issued
2024-07-09T11:25:53Z
dc.date.issued
2024-07-09T11:25:53Z
dc.date.issued
2024-07-02
dc.identifier
Brose MS, Capdevilla J, Elisei R, Bastholt L, Führer-Sakel D, Leboulleux S, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocr Relat Cancer. 2024 Jul 2;31(8):e230354.
dc.identifier
https://hdl.handle.net/11351/11685
dc.identifier
10.1530/ERC-23-0354
dc.identifier.uri
http://hdl.handle.net/11351/11685
dc.description.abstract
Differentiated thyroid cancer; Multikinase inhibitor; Progression-free survival
dc.description.abstract
Cáncer de tiroides diferenciado; Inhibidor de multiquinasa; Supervivencia libre de progresión
dc.description.abstract
Càncer de tiroides diferenciat; Inhibidor de multiquinasa; Supervivència lliure de progressió
dc.description.abstract
The VERIFY study aimed to determine the efficacy of vandetanib in patients with differentiated thyroid cancer (DTC) that is either locally advanced or metastatic and refractory to radioiodine (RAI) therapy. Specifically, VERIFY is a randomized, double-blind, multicenter phase III trial aimed to determine the efficacy and safety of vandetanib in tyrosine kinase inhibitor-naive patients with locally advanced or metastatic RAI-refractory DTC with documented progression (NCT01876784). Patients were randomized 1:1 to vandetanib or placebo. The primary endpoint was progression-free survival (PFS). Secondary endpoints included best objective response rate, overall survival (OS), safety, and tolerability. Patients continued to receive randomized treatment until disease progression or for as long as they were receiving clinical benefit unless criteria for treatment discontinuation were met. Following randomization, 117 patients received vandetanib, and 118 patients received a placebo. Median PFS was 10.0 months in the vandetanib group and 5.7 months in the placebo group (hazard ratio: 0.75; 95% CI: 0.55–1.03; P = 0.080). OS was not significantly different between treatment arms. Common Terminology Criteria for Adverse Events (CTCAE) of grade ≥3 were reported in 55.6% of patients in the vandetanib arm and 25.4% in the placebo arm. Thirty-three deaths (28.2%; one related to study treatment) occurred in the vandetanib arm compared with 16 deaths (13.6%; two related to treatment) in the placebo arm. No statistically significant improvement was observed in PFS in treatment versus placebo in patients with locally advanced or metastatic, RAI-refractory DTC. Moreover, active treatment was associated with more adverse events and more deaths than placebo, though the difference in OS was not statistically significant.
dc.description.abstract
This study was sponsored by Sanofi.
dc.format
application/pdf
dc.publisher
Bioscientifica
dc.relation
Endocrine-Related Cancer;31(8)
dc.relation
https://doi.org/10.1530/ERC-23-0354
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
Tiroide - Càncer -Tractament
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Isòtops radioactius en farmacologia
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Thyroid Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Halogens::Iodine::Iodine Isotopes::Iodine Radioisotopes
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias de la tiroides
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::halógenos::yodo::isótopos del yodo::radioisótopos del yodo
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
